Related papers: Estimating a Personalized Basal Insulin Dose from …

We propose a model-free artificial pancreas (AP) for people with type 1 diabetes. The algorithmic parameters are tuned to a virtual population of 1,000,000 individuals, and the AP repeatedly estimates the basal and bolus insulin…

We present a fully closed-loop design for an artificial pancreas (AP) which regulates the delivery of insulin for the control of Type I diabetes. Our AP controller operates in a fully automated fashion, without requiring any manual…

Around a third of type 2 diabetes patients (T2D) are escalated to basal insulin injections. Basal insulin dose is titrated to achieve a tight glycemic target without undue hypoglycemic risk. In the standard of care (SoC), titration is based…

Despite recent advances in insulin preparations and technology, adjusting insulin remains an ongoing challenge for the majority of people with type 1 diabetes (T1D) and longstanding type 2 diabetes (T2D). In this study, we propose the…

In this paper, we present a model free approach to calculate long-acting insulin doses for Type 2 Diabetic (T2D) subjects in order to bring their blood glucose (BG) concentration to be within a safe range. The proposed strategy tunes the…

Modern treatments for Type 1 diabetes (T1D) use devices known as artificial pancreata (APs), which combine an insulin pump with a continuous glucose monitor (CGM) operating in a closed-loop manner to control blood glucose levels. In…

Calculating mealtime insulin doses poses a significant challenge for individuals with Type 1 Diabetes (T1D). Doses should perfectly compensate for expected post-meal glucose excursions, requiring a profound understanding of the individual's…

People with type 1 diabetes (T1D) lack the ability to produce the insulin their bodies need. As a result, they must continually make decisions about how much insulin to self-administer to adequately control their blood glucose levels.…

Diabetes cases worldwide have risen steadily over the past decades, lending urgency to the search for more efficient, effective, and personalized ways to treat the disease. Current treatment strategies, however, may fail to maintain…

People with Type 1 diabetes (T1D) require regular exogenous infusion of insulin to maintain their blood glucose concentration in a therapeutically adequate target range. Although the artificial pancreas and continuous glucose monitoring…

This paper presents a novel multi-agent reinforcement learning (RL) approach for personalized glucose control in individuals with type 1 diabetes (T1D). The method employs a closed-loop system consisting of a blood glucose (BG) metabolic…

High quality real world datasets are essential for advancing data driven approaches in type 1 diabetes (T1D) management, including personalized therapy design, digital twin systems, and glucose prediction models. However, progress in this…

Diabetes, a chronic condition that impairs how the body turns food into energy, i.e. blood glucose, affects 38 million people in the US alone. The standard treatment is to supplement carbohydrate intake with an artificial pancreas, i.e. a…

Objective: The design of an Artificial Pancreas (AP) to regulate blood glucose levels requires reliable control methods. Model Predictive Control has emerged as a promising approach for glycemia control. However, model--based control…

Self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) are commonly used by type 1 diabetes (T1D) patients to measure glucose concentrations. The proposed adaptive basal-bolus algorithm (ABBA) supports inputs from…

Background: Type 2 diabetes (T2D) is a prevalent chronic disease with a significant risk of serious health complications and negative impacts on the quality of life. Given the impact of individual characteristics and lifestyle on the…

The existing adaptive basal-bolus advisor (ABBA) was further developed to benefit patients under insulin therapy with multiple daily injections (MDI). Three different in silico experiments were conducted with the DMMS.R simulator to…

While the Artificial Pancreas is effective in regulating the blood glucose in the safe range of 70-180 mg/dl in type 1 diabetic patients, the high intra-patient variability, as well as exogenous meal disturbances, poses a serious challenge.…

Patients with Type I Diabetes (T1D) must take insulin injections to prevent the serious long term effects of hyperglycemia - high blood glucose (BG). Patients must also be careful not to inject too much insulin because this could induce…

People with type 1 diabetes (T1D) struggle to calculate the optimal insulin dose at mealtime, especially when under multiple daily injections (MDI) therapy. Effectively, they will not always perform rigorous and precise calculations, but…